Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration

Iveric Bio Inc ISEE has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary to age-related macular degeneration (AMD).
GATHER1 18 month post-hoc analyses show that Zimura 2 mg can potentially impact earlier stages of dry AMD before G.A.
A 19.6% reduction in the rate of progression from drusen to nascent G.A. (iRORA/cRORA) compared to sham was observed, representing a relative risk reduction of 72%.
iRORA/cRORA are earlier forms of dry AMD.
A 21.8% reduction in the rate of progression from iRORA to cRORA compared to sham, equivalent to 52% risk reduction.
The company will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2.
It expects to complete enrollment in late July.
Topline data from GATHER2 is expected in the 2H of 2022.
ISEE will hold a webcast today at 10:00 a.m. E.T.
Price Action: ISEE shares are up 6.12% at $6.24 in the premarket session on the last check Friday.